Kazinol B

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Kazinol B 是一种带有二甲基吡喃环的异戊二烯化黄烷，是一氧化氮 (NO) 生成的抑制剂。Kazinol B 通过胰岛素-Akt 信号通路和 AMPK 激活增强葡萄糖摄取，从而改善胰岛素敏感性。Kazinol B 具有用于糖尿病研究的潜力。

Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research.

———

Kazinol B (2, 10 and 20 μM; 72 hours) shows no toxicity to adipocytes in 3T3-L1 cells.Kazinol B (2-20 μM; 72 hours) dose-dependently increases lipid accumulation by 2.4-fold (at 20 μM) treatment as compared with MDI-treated cells. Kazinol B (2-20 μM; 5 days) dose-dependently increases PPARγ and C/EBPα protein and mRNA levels in MDI-treated 3T3-L1 adipocytes. Kazinol B increases the mRNA level of adiponectin in a dose-dependent manner. Kazinol B (2-20 μM; 24 hours) increases the retained 2 NBDG-fluorescence in cells in a dose-dependent manner in differentiated 3T3-L1 adipocytes and C2C12 myoblasts. Kazinol B dependently increases the MDI-stimulated GLUT4 mRNA level up to 4.7-fold as compared with MDI-only treated cells. Kazinol B (10-20 μM; pre-treated for 1 h followed by 1 h insulin) dose-dependently increases insulin-dependent Akt phosphorylation. Kazinol B alone strongly induces Akt phosphorylation compared with untreated cells. Kazinol B also increased insulin-stimulated AMPK phosphorylation. Kazinol B (6.25, 12.5, 25, 50 μM; 18 hours) dose-dependently reduces amounts of iNOS protein in macrophages (RAW 264.7 cells) activated by LPS (1 ug/mL).

小构树醇B

Others

Other Targets

———

———

———

99624-27-8

392.49

C25H28O4

>98% (HPLC)

———

C(C=C(C)C)C1=C(C=C2C(=C1O)OC(C)(C)C=C2)[C@H]3OC=4C(CC3)=CC=C(O)C4

C(C=C(C)C)C1=C(C=C2C(=C1O)OC(C)(C)C=C2)[C@H]3OC=4C(CC3)=CC=C(O)C4

(-20℃)

With Ice Pack

≥ 2 years